Kellie B. Haworth

First-in-Human Intravenous Seprehvir in Young Cancer Patients: A Phase 1 Clinical Trial

Keri A. Streby, Mark A. Currier, Melinda Triplet et al. · Molecular Therapy · 2019 · 61 citations · Full text

Pharmacy, Oncology, Pharmacology +16

Immune profiling of NF1-associated tumors reveals histologic subtype distinctions and heterogeneity: implications for immunotherapy

Kellie B. Haworth, Michael Arnold, Christopher R. Pierson et al. · Oncotarget · 2017 · 60 citations · Full text

Life Sciences, Immunology, Oncology +17

Oncolytic Herpes Virus rRp450 Shows Efficacy in Orthotopic Xenograft Group 3/4 Medulloblastomas and Atypical Teratoid/Rhabdoid Tumors

Adam Studebaker, Brian Hutzen, Christopher R. Pierson et al. · Molecular Therapy — Oncolytics · 2017 · 46 citations · Full text

Medicine, Oncology, Pharmacology +14

Oncolytic HSV virotherapy in murine sarcomas differentially triggers an antitumor T-cell response in the absence of virus permissivity

Jennifer L. Leddon, Chun‐Yu Chen, Mark A. Currier et al. · Molecular Therapy — Oncolytics · 2014 · 44 citations · Full text

Life Sciences, Immunology, Oncology +17

Interplay of Isoprenoid and Peptide Substrate Specificity in Protein Farnesyltransferase

Sarah A. Reigard, Todd J. Zahn, Kellie B. Haworth et al. · Biochemistry · 2005 · 24 citations

Life Sciences, Biochemistry, Molecular Biology +15